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AbstrAct
background Screening of patients with familial 
adenomatous polyposis (FAP) have led to a substantial 
reduction in mortality due to colorectal cancer (CRC). 
Recent guidelines suggest that surveillance of non-
intestinal malignancies should also be considered in 
those patients. However, the value of these surveillance 
programmes is unknown. The aims of this study were (1) 
to assess the occurrence of extracolonic malignancies 
in a large series of adenomatous polyposis coli (APC) 
mutation carriers and (2) to evaluate the causes of death.
Methods All APC mutation carriers were selected from 
the Dutch polyposis registry. Data on causes of death 
were collected. Pathology reports were retrieved from the 
Dutch Pathology Registry.
results A total of 85 extracolonic malignancies were 
diagnosed in 74 of 582 APC mutation carriers. Duodenal 
and skin cancers were the most prevalent cancers. 
Thyroid cancer was observed in only 1.5% of the cases. 
The main cause of death was cancer (59% of all deaths), 
with 42% due to CRC and 21% due to duodenal cancer. 
One patient died from thyroid cancer. The second and 
third most common causes of death were cardiovascular 
disease (13% of all deaths) and desmoid tumours (11% 
of all deaths), respectively.
conclusion Extending surveillance programmes to 
other cancers will not contribute significantly to the 
survival of patients with FAP.
IntroductIon
Familial adenomatous polyposis (FAP) is an auto-
somal dominantly inherited disease caused by 
germline mutations in the adenomatous polyposis 
coli (APC) gene.1 FAP is characterised by the devel-
opment of hundreds to thousands of colorectal 
adenomas, and unless prophylactic colectomy is 
performed the risk of colorectal cancer (CRC) is 
almost 100%. While nearly all mutation carriers 
also develop duodenal adenomas, the risk of 
duodenal cancer is significantly lower, estimated at 
around 5% to 15%.2 3 Less frequently, other extra-
colonic cancers may be observed such as cancers 
of the thyroid, brain, stomach, pancreas, liver and 
desmoid tumours. Desmoid tumours are histolog-
ically benign fibroblastic tumours that are locally 
aggressive but lack metastatic potential.
During the 1980s and 1990s, polyposis regis-
tries were established with the aim of promoting 
participation in colorectal and upper gastrointes-
tinal (GI) surveillance programmes to prevent intes-
tinal cancer. Establishment of these registries has 
resulted in earlier diagnosis and significant decrease 
in incidence of CRC, and an increase in the life 
expectancy of patients with FAP.4–6 As a conse-
quence, studies began to report a shift in the causes 
of death in those patients and today, beside CRC, 
the main reported causes of death are duodenal 
cancer and desmoid tumours.7 8
An important and still unanswered question 
is whether life expectancy of patients with FAP 
can be further improved by extending existing 
surveillance programmes to other organs such 
as the thyroid, stomach, liver or pancreas. Deci-
sions on surveillance of a particular organ should 
be based on the criteria proposed by Wilson and 
Jungner.9 Most important among these criteria are 
the following requirements: (1) the disease should 
be a common manifestation in the target group, 
(2) available screening tools should be highly sensi-
tive and specific (and not too burdensome), and 
(3) early treatment should improve the prognosis 
and increase life expectancy.
Previous studies have reported risks that vary 
widely for cancers of the thyroid, liver and pancreas 
in FAP. As a consequence, there is still no consensus 
regarding the need for additional surveillance 
recommendations for these cancers.
The aims of this study were (1) to assess the 
occurrence of extracolonic malignancies and benign 
tumours in a large series of patients with FAP with 
a proven APC mutation known from the Dutch 
polyposis registry and (2) to evaluate whether these 




The Dutch Polyposis Registry was established by the 
Netherlands Foundation for Detection of Heredi-
tary Tumours (NFDHT) in 1985. The main objec-
tive of the registry is to promote early detection of 
upper and lower GI cancers through coordination 
of lifelong surveillance of at-risk patients.10 Patients 
with FAP are referred to this national registry by 
gastroenterologists, surgeons or clinical geneti-
cists. At the time of registration, written informed 
consent for collection of personal and medical data 
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is provided by all patients. At regular intervals (usually annu-
ally), the registry sends out reminders to gastroenterologists to 
prompt patient screening, and the results of these endoscopies 
and results of histological examinations are then sent to the 
registry. To date, >2000 patients with a clinical diagnosis of 
FAP have been registered, of which >500 are proven APC germ-
line mutation carriers. This study was approved by the research 
committee of the registry.
cross-referencing the dutch Polyposis registry to the 
national Pathology registry
For this study, we selected all patients with FAP with a proven 
germline APC mutation in the Dutch polyposis registry. All 
medical information, age at last follow-up and mortality 
including cause of death and age at death were collected. 
The medical files usually contain histology reports of surgical 
specimens or biopsies. However, to improve the quality of the 
medical data, we cross-referenced polyposis registry data to the 
‘nationwide network and registry of histopathology and cyto-
pathology in the Netherlands (PALGA)’, which was established 
in 1971.11 The PALGA database does not contain identifying 
patient data, but only pseudonyms based on this data. Pseud-
onymisation of the Dutch polyposis registry was carried out by a 
trusted third party to maintain data confidentiality.
statistical analysis
Descriptive statistical analysis was used. Observations were from 
1971 or time of registration to death, loss to follow-up or end 
of the study (1 May 2014). Data were analysed and calculations 
were carried out using SPSS V.22.0.
results
study population
A total of 567 proven APC mutation carriers registered at the 
Dutch Polyposis Registry were enrolled in the study. All included 
patients were cross-referenced to the PALGA registry. Of those, 
two patients were excluded due to missing clinical data. An 
additional search in the polyposis registry identified a further 
17 patients with FAP with a confirmed APC mutation who were 
also included in the study. Using the records of the Dutch Polyp-
osis Registry, the occurrence of extracolonic malignancies was 
studied in these 17 patients. The total group of patients was 582 
(49.7% male). The mean age at last follow-up was 39.9 years.
benign extracolonic lesions
Of the 565 patients initially enrolled in the study, 191 (33.8%) 
had at least one pathology report with evidence of duodenal 
adenomatous polyposis. Fundic gland polyposis was reported in 
102 (18.1%) patients, and 24 (4.2%) patients had at least one 
gastric adenoma, all located in the antrum.
Desmoid tumours confirmed by a histology report were 
described in 27 (4.8%) of the carriers. A total of 38 patients 
(6.7%) had a benign skin tumour of several types. Lipomas and 
osteomas were documented in 11 (1.9%) and 7 (1.2%) patients, 
respectively. Other reported tumours included a benign thyroid 
tumour (one patient), adrenal tumours (two patients) and 
ovarian cystadenomas (three patients).
Malignant extracolonic lesions
A total of 85 extracolonic malignancies were documented by 
pathology report in 582 APC mutation carriers, and 74 (12.7%) 
of the carriers had at least one malignant extracolonic lesion. 
The frequency of extracolonic malignancies and mean age at 
diagnosis are shown in table 1.
Duodenal cancer and skin cancers (basal cell carcinoma, squa-
mous cell carcinoma and melanoma) were the most common 
extracolonic cancers (in 3.1% and 2.2% of patients, respec-
tively), followed by thyroid cancer (1.5%). Six of 294 (2.0%) 
female patients were diagnosed with breast cancer, at a mean 
age of 43.5 years. In four of these patients, the breast cancer was 
diagnosed before 40 years of age.
Thyroid cancer was documented in nine patients (1.5%). 
Seven female patients (2.4% of all female patients) were diag-
nosed with papillary thyroid cancer, with a mean age of 33.5 
years at diagnosis. Duodenal cancer was observed in 18 patients 
including 14 of ampullary origin (3.1%), hepatoblastoma in 4 
(0.7%), bladder cancer in 4 (0.7%) and pancreatic malignancy, 
malignant brain tumour and meningioma were each observed in 
2 patients.
cause of death
In addition to CRC (25% of all deaths), extracolonic cancers 
(33.9%) and cardiovascular disease (12.5%) were the two 
most common causes of death in Dutch APC mutation carriers. 
Duodenal cancers and desmoid tumours were responsible for 
12.5% and 10.7% of deaths, respectively. One patient died from 
thyroid cancer at the age of 78 years. Two patients died due to 
complications of Whipple surgery and one patient committed 
suicide at the age of 36 years. Table 2 describes the causes and 
age at death in APC mutation carrier patients in the Dutch 
polyposis registry.
dIscussIon
The most common extracolonic cancers found in this study 
were duodenal cancer and skin tumours. The frequency of other 
FAP-associated cancers such as cancer of the thyroid, liver (hepa-
toblastoma), brain and stomach was low. Among the benign 
lesions, the most frequent were fundic gland polyps, duodenal 
and gastric adenomas and desmoid tumours. The most prevalent 
cause of death was cancer (59%), with 42% of the cancer deaths 
due to CRC and 21% of the cancer deaths due to duodenal 
cancer. The second and third most common causes of death 
table 1 Extracolonic cancers in 582 FAP patients with APC mutation
site of cancer n (%) Gender (m/f)
Mean age at 
diagnosis (range)
Duodenum 18 (3.1) 8/10 52.1 (32–79)
Skin 13 (2.2) 8/5 52.1 (26–67)
Thyroid 9 (1.5) 1/8 38.6 (19–53)
Lung 7 (1.2) 4/3 50.1 (35–61)
Breast 6 (2.0)* 0/6 43.5 (33–68)
Bladder 4 (0.7) 3/1 51.5 (31–64)
Hepatoblastoma 4 (0.7) 3/1 1.8 (1–3)
Unknown primary 4 (0.7) 3/1 42.5 (23–55)
Liver 3 (0.5) 3/0 31 (17–68)
Endometrium 2 (0.7)* 0/2 44.5 (41–48)
Brain tumour 2 (0.3) 1/1 31.0 (13–49)
Meningioma 2 (0.3) 1/1 40.0 (46–34)
Pancreas 2 (0.3) 1/1 54.5 (40–69)
Others† 9 (1.5) 5/4 46.6 (26–77)
*% calculated in female patients.
†Ovary, cervix, vagina, lymphoma, larynx, vocal cords, parotid, prostate, stomach.
APC, adenomatous polyposis coli; FAP, familial adenomatous polyposis; m/f, male/
female.
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were cardiovascular disease (12.5% of all deaths) and desmoid 
tumours (10.7% of all deaths), respectively.
A number of studies have reported frequencies for extraco-
lonic cancers in FAP, but results vary widely. For instance, the 
prevalence rates of thyroid cancer in the literature vary from 
0.4% to 11.8%.12–14 Reported frequencies appear to depend 
on the type of study, that is, prospective versus retrospec-
tive studies or large registry studies versus small series. The 
frequencies found in our study were similar to those reported 
in previous registry-based studies (1%–2%). Likewise, the 
frequencies of brain tumours, pancreatic cancer and hepato-
blastoma we observed were also equal to rates reported in the 
literature at around <1%–2%.15 16
Prevalence of duodenal cancer was relatively low at 3%, which 
may be due to upper GI surveillance and the implementation of 
prophylactic duodenectomy in patients with advanced duodenal 
polyposis.17 In this study, we identified only one patient with 
gastric cancer, in agreement with earlier studies that showed that 
the incidence of this cancer is not increased in FAP families in 
Western countries. By contrast, studies from Japan and South 
Korea report gastric cancer rates of 3%–4%.18 19
Although the incidence of other cancers (eg, cancer of lung 
and breast) was not increased, interestingly, the age of breast 
cancer diagnosis observed in our patients with polyposis was 
relatively low.
One of the strengths of this study was that we were able to 
assemble a very large cohort of proven APC mutation carriers 
with a follow-up of more than 25 years. In addition, cross-ref-
erencing the polyposis registry with the PALGA database 
allowed us to expand the number of patients with pathologically 
confirmed tumours.
The limitation of the study was that some extracolonic 
tumours such as brain tumours and desmoid tumours were not 
always confirmed by pathology and therefore may have been 
underestimated. The same is probably true for some benign 
lesions, such as fundic gland polyps, because the endoscopic 
appearance of fundic gland polyposis in a patient with FAP 
is very typical and biopsies for pathological confirmation are 
often not obtained. Furthermore, the PALGA database was 
established in 1971 and gradually extended its coverage to 
100% by 1991. As a consequence, some tumours might have 
been missed.
What are the implications of this study for clinical practice? 
The consensus in the current guidelines is that patients should 
be screened for duodenal adenomas/cancer, in addition to 
surveillance of the colon. However, consensus has not yet been 
reached with respect to other non-intestinal cancers, including 
cancers of the thyroid, pancreas and liver.15 20 21
If we apply the above-mentioned criteria developed by Wilson 
and Jungner to decision-making on thyroid cancer surveillance, 
we can conclude that the risk of thyroid cancer found in this 
study and other registry studies is relatively low, with women 
showing the highest risk. Although highly sensitive screening 
tools for thyroid cancer like ultrasonography (US) and fine 
needle aspiration (FNA) biopsy are available, a major disadvan-
tage is that regular examination will frequently reveal benign 
lesions that result in FNA biopsy. These findings and subsequent 
biopsies represent a burden for patients and may also cause 
substantial anxiety. The most important finding of our study 
was that only one patient died from this cancer, at the age of 
78 years. On the basis of these considerations, we do not recom-
mend thyroid cancer surveillance in patients with FAP outside of 
research programmes.
Regarding the need for liver tumour (hepatoblastoma) surveil-
lance, the prevalence of this type of tumour in our and other 
studies was very low, at around 1%. In addition, none of the four 
patients in our study died as a result from this tumour. Because 
hepatoblastoma is a disease that occurs in early childhood, 
a consequence of the decision to screen mutation carriers for 
these tumours would be that APC mutation analysis would have 
to be performed at birth rather than from the age of between 
10 and 12 years, as is current practice. This change in policy 
would lead to stigmatisation of children found to be mutation 
carriers. In view of these considerations, we do not recommend 
surveillance of mutation carriers for liver tumours outside of 
research programmes.
Finally, although cancer of the pancreas appears to be associ-
ated with FAP, the prevalence is very low and we do not recom-
mend screening.
In conclusion, the life expectancy of patients with FAP has 
increased substantially following implementation by registries 
of screening programmes for colorectal and duodenal cancer. 
On the basis of our data, we conclude that extending these 
surveillance programmes to extraintestinal-associated cancers 
will not further improve life expectancy in APC mutation 
carriers.
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